Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by XTX Topco Ltd

XTX Topco Ltd decreased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 69.1% in the second quarter, Holdings Channel reports. The institutional investor owned 1,057 shares of the biopharmaceutical company’s stock after selling 2,364 shares during the period. XTX Topco Ltd’s holdings in Regeneron Pharmaceuticals were worth $1,111,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of the company. Mark Sheptoff Financial Planning LLC grew its position in shares of Regeneron Pharmaceuticals by 35.0% during the 2nd quarter. Mark Sheptoff Financial Planning LLC now owns 135 shares of the biopharmaceutical company’s stock valued at $142,000 after acquiring an additional 35 shares during the period. MRP Capital Investments LLC purchased a new position in Regeneron Pharmaceuticals during the second quarter worth approximately $306,000. Vanguard Personalized Indexing Management LLC grew its holdings in Regeneron Pharmaceuticals by 13.4% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 9,559 shares of the biopharmaceutical company’s stock valued at $10,047,000 after purchasing an additional 1,129 shares during the period. Meiji Yasuda Asset Management Co Ltd. increased its position in shares of Regeneron Pharmaceuticals by 5.4% in the second quarter. Meiji Yasuda Asset Management Co Ltd. now owns 2,314 shares of the biopharmaceutical company’s stock valued at $2,432,000 after buying an additional 119 shares in the last quarter. Finally, Argent Trust Co raised its stake in shares of Regeneron Pharmaceuticals by 1.3% during the 2nd quarter. Argent Trust Co now owns 2,370 shares of the biopharmaceutical company’s stock worth $2,491,000 after buying an additional 31 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Marion Mccourt sold 1,137 shares of the business’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $1,047.11, for a total value of $1,190,564.07. Following the sale, the executive vice president now directly owns 12,931 shares of the company’s stock, valued at approximately $13,540,179.41. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at approximately $18,447,575.65. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Marion Mccourt sold 1,137 shares of the business’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $1,047.11, for a total transaction of $1,190,564.07. Following the sale, the executive vice president now owns 12,931 shares in the company, valued at $13,540,179.41. The disclosure for this sale can be found here. Insiders sold a total of 10,026 shares of company stock valued at $11,498,705 over the last 90 days. 7.48% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on REGN. Morgan Stanley dropped their price target on shares of Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating on the stock in a research note on Thursday, July 11th. StockNews.com raised shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, September 10th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $1,152.00 price target on shares of Regeneron Pharmaceuticals in a research note on Thursday, June 27th. Piper Sandler boosted their price objective on Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the stock an “overweight” rating in a research note on Friday, August 23rd. Finally, Wells Fargo & Company raised their target price on Regeneron Pharmaceuticals from $1,125.00 to $1,200.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd. One investment analyst has rated the stock with a sell rating, two have given a hold rating, sixteen have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $1,111.30.

Regeneron Pharmaceuticals Stock Down 0.4 %

REGN stock opened at $1,145.03 on Friday. The firm has a market cap of $126.17 billion, a PE ratio of 33.83, a PEG ratio of 3.93 and a beta of 0.12. Regeneron Pharmaceuticals, Inc. has a one year low of $769.19 and a one year high of $1,211.20. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.62 and a current ratio of 5.44. The firm’s 50 day moving average price is $1,131.75 and its 200-day moving average price is $1,032.21.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, beating the consensus estimate of $8.93 by $2.63. The business had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The company’s quarterly revenue was up 12.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $8.79 EPS. On average, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.8 EPS for the current year.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.